A Pilot Study to Evaluate the Effects of Vaccinations with HLA-A2-Restricted Glioma Antigen-Peptides with Poly-ICLC for Children with Newly Diagnosed Malignant Brain Stem Gliomas, Non-Brainstem High-Grade Gliomas, Recurrent Low-Grade Gliomas or Recurrent High Grade Gliomas
Latest Information Update: 10 Dec 2024
At a glance
- Drugs SL 701 (Primary) ; Poly ICLC
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions
Most Recent Events
- 06 Dec 2024 Status changed from active, no longer recruiting to completed.
- 06 Dec 2024 Status changed from active, no longer recruiting to completed.
- 31 Oct 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.